Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 5Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Gastrointestinal 1

Conditions

Head and Neck Neoplasms 2Neoplasms, Squamous Cell 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 57pembrolizumab 54Cetuximab 43Radiotherapy 35Docetaxel 21Radiotherapy, Intensity-Modulated 20Paclitaxel 19Nivolumab 18Fluorouracil 18Carboplatin 17Radiation 14Radiosurgery 9Magnetic Resonance Spectroscopy 8Gemcitabine 8Everolimus 8Biopsy 8Surgical Procedures, Operative 7Oxaliplatin 7Cyclophosphamide 7durvalumab 6avelumab 6Erlotinib Hydrochloride 6Capecitabine 6spartalizumab 5epacadostat 5Surveys and Questionnaires 5Platinum 5Immunoglobulin G 5Gefitinib 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × zalutumumab × Head & Neck × Clear all
NCT00707655 2023-08-03

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Genmab

Phase 1/2 Terminated
8 enrolled 10 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00401401 2011-12-23

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Genmab

Phase 1/2 Terminated
30 enrolled 13 charts
Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡